SCHEMBL4193697

SCHEMBL4193697

Cn1c(N)c(N=O)c(=O)n(C)c1=O

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CASP6 P55212 1/20 0.66
POLB P06746 4/20 0.47
KMT2A Q03164 4/20 0.47
ALDH1A1 P00352 4/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 2/20 0.47
HPGD P15428 1/20 0.47
HIF1A Q16665 1/20 0.47
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
HTT P42858 2/20 0.38
LMNA P02545 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
AOC3 Q16853 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
PABPC1 P11940 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1546702 0.77 CASP6 (0.50) CASP6POLBKMT2AALDH1A1MAPT
SCHEMBL7321137 0.77 CASP6 (0.50) CASP6POLBKMT2AALDH1A1MAPT
SCHEMBL1545988 0.75 ALDH1A1 (0.47) CASP6KMT2AALDH1A1MAPTMEN1
SCHEMBL8830896 0.74 GSK3A (0.49) CASP6POLBKMT2AALDH1A1MAPT
SCHEMBL4255826 0.74 CASP6 (0.46) CASP6KMT2AALDH1A1MAPTMEN1
SCHEMBL9326371 0.74 POLB (0.55) CASP6POLBKMT2AALDH1A1MAPT
SCHEMBL4809819 0.73 CASP6 (0.45) CASP6POLBKMT2AALDH1A1MAPT
SCHEMBL4379829 0.73 ALDH1A1 (0.47) CASP6POLBKMT2AALDH1A1MAPT
SCHEMBL3079303 0.73 PDE5A (0.51) CASP6POLBKMT2AALDH1A1MAPT
SCHEMBL4379825 0.73 ALDH1A1 (0.47) CASP6POLBKMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106046004-A Total synthesis method for theacrine 上海佰特因医药科技有限公司 2016-10-26 CN claimed
EP-0681868-B1 Carbon containing catalyst support and process for its preparation KATALEUNA GMBH CATALYSTS (DE) 2003-07-30 EP claimed
US-5510484-A Process for preparing 1,3-dimethy-4,5-diaminouracil BOEHRINGER INGELHEIM KG (DE) 1996-04-23 US claimed
EP-0681868-A1 Carbon containing catalyst support and process for its preparation LEUNA-Katalysatoren GmbH (DE) 1995-11-15 EP claimed
EP-0619310-A1 Improved process for the preparation of 1,3-dimethyl-4,5-diamino-uracil BOEHRINGER INGELHEIM KG (DE) 1994-10-12 EP claimed
CN-118908901-A Method for continuously synthesizing aminophylline intermediate 2 through nitrosation 台州普渡机械设备有限公司 2024-11-08 CN disclosed
US-12054768-B2 Methods for detecting agglutination and compositions for use in practicing the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-08-06 US disclosed
US-20240109892-A1 POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME NATIONAL INSTITUTES OF HEALTH 2024-04-04 US disclosed
US-11772085-B2 Far superior oxidation catalysts based on macrocyclic compounds CARNEGIE MELLON UNIVERSITY (US) 2023-10-03 US disclosed
CN-111072574-B 5, 6-diamino-1, 3-dialkyl substituted uracil and its preparation method 广东工业大学 2023-03-14 CN disclosed
EP-4123031-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME The Regents of The University of California (US) 2023-01-25 EP disclosed
WO-2022159818-A1 POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-07-28 WO disclosed
EP-0586523-A4 DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF UNIV YALE (US) 1995-11-29 EP disclosed
EP-0681868-A1 Carbon containing catalyst support and process for its preparation LEUNA-Katalysatoren GmbH (DE) 1995-11-15 EP disclosed
EP-0681868-A1 Carbon containing catalyst support and process for its preparation LEUNA-Katalysatoren GmbH (DE) 1995-11-15 EP disclosed
EP-0619310-A1 Improved process for the preparation of 1,3-dimethyl-4,5-diamino-uracil BOEHRINGER INGELHEIM KG (DE) 1994-10-12 EP disclosed
EP-0619310-A1 Improved process for the preparation of 1,3-dimethyl-4,5-diamino-uracil BOEHRINGER INGELHEIM KG (DE) 1994-10-12 EP disclosed
EP-0586523-A1 DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF YALE UNIVERSITY (US) 1994-03-16 EP disclosed
US-5213972-A Production of thymidine and deoxyuridine, intermediates for AZT CHEMGEN CORPORATION (US) 1993-05-25 US disclosed
WO-1992020816-A1 DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF YALE UNIVERSITY (US) 1992-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109892-A1 POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME MACROD2, MACROD1, PARG CASP6 1529/4885POLB 621/4885KMT2A 1290/4885
US-11772085-B2 Far superior oxidation catalysts based on macrocyclic compounds SOD1, ME3, ME2 CASP6 3710/4885POLB 195/4885KMT2A 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.